Key result
The leader compound 3a demonstrated micromolar antiviral activity against SARS-CoV-2 and submicromolar activity against respiratory syncytial virus without noticeable host cell toxicity.
Why the study?
Emerging and re-emerging viral outbreaks periodically cause epidemics and pandemics, creating an urgent need for new antiviral drugs.
A novel hydroxybenzo[4,5]imidazo[1,2-c]pyrimidin-1(2H)-one scaffold-based nucleoside analog demonstrated promising in vitro antiviral activity against SARS-CoV-2 and respiratory syncytial virus without significant host cell toxicity.
Emerging and re-emerging viruses periodically cause outbreaks and epidemics around the world, which ultimately lead to global events such as the COVID-19 pandemic. Thus, the urgent need for new antiviral drugs is obvious. Over more than a century of antiviral development, nucleoside analogs have proven to be promising agents against diversified DNA and RNA viruses. Here, we present the synthesis and evaluation of the antiviral activity of nucleoside analogs and their deglycosylated derivatives based on a hydroxybenzo[4,5]imidazo[1,2-c]pyrimidin-1(2H)-one scaffold. The antiviral activity was evaluated against a panel of structurally and phylogenetically diverse RNA and DNA viruses. The leader compound showed micromolar activity against representatives of the family Coronaviridae, including SARS-CoV-2, as well as against respiratory syncytial virus in a submicromolar range without noticeable toxicity for the host cells. Surprisingly, methylation of the aromatic hydroxyl group of the leader compound resulted in micromolar activity against the varicella-zoster virus without any significant impact on cell viability. The leader compound was shown to be a weak inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase. It also inhibited biocondensate formation important for SARS-CoV-2 replication. The active compounds may be considered as a good starting point for further structure optimization and mechanistic and preclinical studies.
No takes yet. Share an insight, caveat, or question.
Kamzeeva et al. (2023) studied Viral infections (Coronaviruses, RSV, VZV). Benzo[4,5]imidazo[1,2-c]pyrimidinone-based nucleoside derivatives (compound 3a) vs. Reference compounds (e.g., remdesivir, brivudine) and inactive derivatives was evaluated on Antiviral activity (EC50). The leader compound 3a demonstrated micromolar antiviral activity against SARS-CoV-2 and submicromolar activity against respiratory syncytial virus without noticeable host cell toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: